Tesla, EEOC Move Toward Mediation in Racial Harassment Lawsuit 
HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds 
Trump Administration Approves Nvidia H200 AI Chip Sales to China Under New Export Rules 
Zhipu AI Launches GLM-Image Model Trained on Huawei Chips, Boosting China’s AI Self-Reliance Drive 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
U.S. Lawmakers Raise Alarm Over Trump Approval of Nvidia AI Chip Sales to China 
Alphabet Stock Poised for Growth as Bank of America Sees Strong AI Momentum Into 2026 
Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows 
Amazon Reviews Supplier Costs as U.S.–China Tariffs Ease 
NYC Nurses Strike Shuts Down 10 Private Hospitals as 15,000 Demand Safer Staffing and Benefits 
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
Coca-Cola Shelves Costa Coffee Sale After Low Private Equity Offers 
Saks Global Files for Bankruptcy Protection Amid Mounting Luxury Retail Pressures 
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals 
Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny 
Starlink Internet Remains Active in Iran Despite Nationwide Blackout 
U.S. Government Invests $1 Billion in L3Harris Rocket Motor Business to Secure Missile Supply Chain 
LOS ANGELES, April 03, 2017 -- Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against BioAmber Inc. (“BioAmber” or the “Company”) (NYSE:BIOA) concerning possible violations of federal securities laws. Investors who purchased shares (1) pursuant and/or traceable to BioAmber’s secondary public offering on or about January 23, 2017; and/or (2) on the open market from January 23, 2017 through March 16, 2017 inclusive (the “Class Period”), should contact the firm prior to the May 17, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at [email protected].
No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
According to the Complaint, throughout the Class Period, BioAmber made materially false and/or misleading statements and/or failed to disclose that a large customer of the Company that was expected to purchase $2.8 million of succinic acid in the fourth quarter of 2016 postponed the order to 2017; and as a result, the Company’s statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When this information was released to the public, the stock price of BioAmber fell, thus harming investors.
Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding the rights of shareholders.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/
